Evidence map›Paper›PMID 35992154›Full record

ArticleFrontiers in endocrinology2022

Serum α-KL, a potential early marker of diabetes complications in youth with T1D, is regulated by miRNA 192.

Zhenwei Gong, Pedro A Pagán Banchs, Ye Liu, Haoyi Fu, Vincent C Arena, Erick Forno, Ingrid Libman, Jacqueline Ho, Radhika Muzumdar

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Comprehensive bioinformatics andFrontiers in endocrinology · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Zhenwei GongUniversity of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, PA, United States.
Pedro A Pagán BanchsUniversity of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, PA, United States.
Ye LiuUniversity of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, PA, United States.
Haoyi FuDepartment of Biostatistics, School of Public Health, University of Pittsburgh, PA, United States.
Vincent C ArenaDepartment of Biostatistics, School of Public Health, University of Pittsburgh, PA, United States.
Erick FornoUniversity of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, PA, United States.
Ingrid LibmanUniversity of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, PA, United States.
Jacqueline HoUniversity of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, PA, United States.
Radhika MuzumdarUniversity of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, PA, United States.
University of Pittsburgh · USChildren's Hospital of Pittsburgh · USUniversity of Pittsburgh Medical Center · US

Funding

RESEARCH TRAINING IN PEDIATRIC ENDOCRINOLOGY &DIABETEST32DK007729 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MUZUMDAR, RADHIKA HIREN · 1995 to 2020
$3.3M
Obesity and Childhood Asthma: The Role of Adipose TissueR01HL149693 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FORNO, ERICK · 2020 to 2024
$3.0M
NHLBI NIH HHS R01 HL149693NIDDK NIH HHS T32 DK007729
6 · The paper itself

Abstract

Despite the wealth of information on biomarkers of diabetes complications in adults with type 1 diabetes, data in the pediatric population is limited. Diabetic nephropathy (DN), the leading cause of mortality in type 1 diabetes T1D), could be potentially missed in youth, as albuminuria, the current "gold" standard, may be transient and may not reflect permanent renal impairment. Soluble alpha KL has emerged as a potential marker of early diabetic nephropathy. Seventy-nine pediatric patients with type 1 diabetes meeting ISPAD criteria for nephropathy screening were consecutively recruited (90% Caucasian, 51% male, mean age 16.1 ± 3.1 years, duration of T1D 7.2 ± 3.9 years, 2-year average HbA1c 8.0 ± 1.3%, and serum and urine samples were collected for analysis. Serum Klotho (KL) and circulating miRNA levels of select miRNA involved in the pathogenesis of DN were estimated. KL had a strong inverse correlation with diabetes duration and HbA1c, two important risk factors in the development of diabetes complications. Serum miR-192 were negatively associated with KL among children with prolonged duration of diabetes (≥12 years) after adjustment for age and sex. In cell culture, overexpression of miR-192 significantly downregulated KL mRNA and protein levels, and reduced KL levels in the media. miR-192 mimic reduced luciferase activity in a reporter containing the KL 3' UTR (60% compared to controls, p<0.01), and the inhibitor rescued it. Deletion of a potential binding site for miR-192 in the KL 3'UTR completely abolished the effect of miR-192 in the reporter assay, suggesting that KL is a direct target gene of miR-192. Overexpression of miR-192 significantly increased oxidative stress (MDA) and expression of inflammatory and senescence markers IL-6 and p16. Inhibition of miR-192 significantly reduced levels of MDA, IL-6 and p16. In summary, we demonstrate an increase in miR-192 and a decrease in KL levels in children with prolonged duration of T1D. We demonstrate a novel role for miR-192 in directly regulating KL levels, and through that, senescence and oxidative stress, key pathological processes in the development of DN. miR-192 and/or KL levels are altered with severity and duration of diabetes and could serve as early biomarkers for DN.

Indexed as

Diabetes Mellitus, Type 1Diabetic NephropathiesMicroRNAsAdolescentAdultBiomarkersChildFemaleGlycated HemoglobinHumansInterleukin-6Klotho ProteinsMaleYoung AdultBiomarkersGlycated HemoglobinInterleukin-6Klotho ProteinsKL protein, humanMicroRNAsMIRN192 microRNA, humanbiomarkerdiabetic nephropathyKlothomiR-192type 1 diabetes mellitus

Identifiers

PMID35992154
PMCPMC9388782
OpenAlexW4289889435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.